U.S. Insurance Stock News

On August 11, 2025, Fluence Energy reaffirmed its fiscal year 2025 revenue guidance at a range of US$2.6 billion to US$2.8 billion, but now expects to reach the lower end of the range due to slower production ramp-up at its new U.S. manufacturing facilities, shifting some anticipated revenue to fiscal year 2026. This delay in production comes as the company maintains its annual recurring revenue guidance and expects the facilities to achieve target capacity by year-end, bolstering its...

NANO Nuclear Energy Inc. recently announced earnings results for the quarter and nine months ended June 30, 2025, reporting a third-quarter net loss of US$7.59 million and a year-to-date net loss of US$32.02 million, both higher than the prior year. Losses per share also widened from the previous year, suggesting increased operational costs or investments contributing to the deeper losses. We'll examine how the larger net loss shapes NANO Nuclear Energy's investment narrative around future...

CF Industries Holdings released its second-quarter 2025 results, reporting US$1.89 billion in sales, steady ammonia production, and updates on share repurchase activity completed under its ongoing buyback program. Notably, management issued full-year guidance projecting gross ammonia output to reach approximately 10 million tons, highlighting continued focus on production scale and operational efficiency. To understand the potential impact on CF Industries Holdings' investment outlook, we'll...

In August 2025, Raymond James upgraded Essex Property Trust to Outperform, emphasizing the company's robust presence in tech-driven West Coast markets and noting improving cash delinquencies as well as early signs of rent growth recovery in Oakland. The upgrade underscores Essex's cost of capital advantage, setting it apart as potentially less exposed to supply pressures affecting multifamily REITs in other regions. We'll now explore how Essex's cost of capital advantage, highlighted in the...

Harmony Biosciences Holdings recently reported second-quarter 2025 earnings, revealing net income of US$39.78 million versus US$11.59 million a year earlier and reaffirmed its full-year 2025 revenue guidance of US$820 million to US$860 million. This sharp improvement in earnings and maintained revenue outlook highlights the company’s operational momentum and management’s confidence in its ongoing business performance. With Harmony Biosciences delivering much higher profits and upholding its...

Earlier this month, Sunrun announced a rapid migration of its operations to Oracle Warehouse Management Cloud and reported strong second-quarter earnings with net income of US$279.77 million, more than doubling year over year. An independent study released by The Brattle Group also revealed that Sunrun's fleet of over 100,000 residential batteries supplied the majority of distributed energy during a major California grid event, underscoring the company's growing influence in the home energy...

Bentley Systems recently completed a share repurchase of 499,143 shares for US$20 million and announced its second quarter 2025 financial results, reporting US$364.11 million in revenue and US$70.48 million in net income. An interesting detail is that despite year-over-year revenue growth, net income for the second quarter was steady, highlighting the company’s emphasis on shareholder returns through continued buyback activity. We'll examine how the blend of rising revenue and steady...

Grindr Inc. recently announced its second quarter 2025 earnings results, reporting sales of US$104.22 million and a net income of US$16.64 million, marking a shift from a net loss for the same period last year. This turnaround to profitability, alongside strong year-over-year revenue growth, reflects the company’s improved operational performance and shifting financial trajectory. Now, we’ll explore how Grindr’s return to profitability could influence its investment narrative and future...

Core Scientific reported its second quarter 2025 earnings on August 8, showing revenue of US$78.63 million compared to US$141.1 million a year earlier, with a net loss of US$936.8 million and basic loss per share from continuing operations of US$0.04. Despite continued year-over-year declines in revenue and net losses, major Wall Street analysts recently upgraded or reaffirmed positive ratings for the company after the earnings report. We’ll examine how improved analyst sentiment, following...

Earlier this month, Dynavax Technologies Corporation raised its full-year 2025 revenue guidance for HEPLISAV-B to a range of US$315 million to US$325 million and posted quarterly results showing second-quarter revenue climbed to US$95.44 million, with net income reaching US$18.72 million. The guidance increase reflects strong performance in the first half, while the earnings report highlights significant year-over-year growth in both revenue and profit margins for the company. To understand...

Kenvue recently reported its second-quarter 2025 earnings, with net income rising to US$420 million from US$58 million a year earlier, while sales declined to US$3,839 million from US$4,000 million; the company also revised its full-year 2025 guidance, now expecting net and organic sales to be down low-single-digits. Alongside the financial update, Kenvue announced the appointment of a new Chief Technology & Data Officer and completed a significant share buyback, indicating both leadership...

Earlier this month, V2X, Inc. filed for a follow-on equity offering of 2,000,000 shares of common stock shortly after reporting a return to profitability in its second-quarter results and reaffirming its full-year revenue guidance. This sequence of events highlights how the company is taking advantage of renewed financial momentum to strengthen its balance sheet through equity financing. We'll explore how V2X’s follow-on equity offering, coming right after its profitability turnaround, may...

In the past week, Claritev Corporation reported second-quarter results showing higher sales at US$241.57 million and a sharply reduced net loss of US$62.64 million, while updating its full-year 2025 revenue guidance to between flat and 2% growth from 2024 levels. The company’s US$400 million universal shelf registration, covering a range of securities, adds financial flexibility to support potential future initiatives and growth plans. We will explore how Claritev’s improving financial...

Vera Therapeutics recently reported a second quarter net loss of US$76.53 million, significantly higher than a year ago, and announced a US$200 million follow-on equity offering of Class A common stock. The concurrent disclosure of increased quarterly losses and a major capital raise highlights potential funding needs and ongoing operational pressures facing the company. We’ll examine how Vera Therapeutics’ expanded capital raise shapes its investment narrative amid growing financial...

The board of Energizer Holdings, Inc. ( NYSE:ENR ) has announced that it will pay a dividend of $0.30 per share on the...

Precigen ( NASDAQ:PGEN ) Second Quarter 2025 Results Key Financial Results Net loss: US$26.6m (loss narrowed by 55...

NasdaqCM:OPXS 1 Year Share Price vs Fair Value Explore Optex Systems Holdings's Fair Values from the Community and...

NasdaqGS:PNFP 1 Year Share Price vs Fair Value Explore Pinnacle Financial Partners's Fair Values from the Community and...

JD.com ( NASDAQ:JD ) Second Quarter 2025 Results Key Financial Results Revenue: CN¥356.7b (up 22% from 2Q 2024). Net...

NasdaqGM:BHST 1 Year Share Price vs Fair Value Explore BioHarvest Sciences's Fair Values from the Community and select...

NasdaqGS:LECO 1 Year Share Price vs Fair Value Explore Lincoln Electric Holdings's Fair Values from the Community and...

NasdaqGM:ATLN 1 Year Share Price vs Fair Value Explore Atlantic International's Fair Values from the Community and...

NasdaqCM:QUIK 1 Year Share Price vs Fair Value Explore QuickLogic's Fair Values from the Community and select yours...

GoodRx Holdings, Inc.'s ( NASDAQ:GDRX ) earnings announcement last week was disappointing for investors, despite the...